Immunotherapy developer Elixiron has closed its series A1 round with capital from investors including Hong Tai Electric Industrial.
Elixiron Immunotherapeutics, a US-based developer of immunotherapies for cancer in addition to neurodegenerative and immunological disorders, has received $27m in a series A1 round featuring electronics manufacturer Hong Tai Electric Industrial.
Investment firm Pangu Capital and venture capital firm Taiwania Capital co-led the round, which included DCI Partners, a subsidiary of investment bank Daiwa Securities Group, as well as financial services firms Mega International Commercial Bank and Fubon Financial Holdings, and private equity firm CDIB Capital Group.
Elixiron was founded…
